Testimony of the Endocrine Society Submitted to the Food and Drug Administration Clinical Chemistry and Clinical Toxicology Devices Panel
"Finally, patients need guidance on using unverified CGM data safely and effectively. FDA’s approval of this change would enable Dexcom to offer patient support and education on the best ways to use unverified CGM data in real time. It would also allow clinicians to offer cogent advice on how to use the data safely and effectively without verification and for Dexcom to offer appropriate support to clinicians around this important topic. "
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.
Register for ENDO 2021, the largest meeting on endocrinology in the world. Our comprehensive agenda will cover all aspects of endocrinology over four days of programming that includes more than 90 live sessions and another 80 sessions available on-demand.